00:30 , Oct 20, 2017 |  BC Week In Review  |  Clinical News

DSMB backs Athenex's Phase III breast cancer trial of Oraxol

Athenex Inc. (NASDAQ:ATNX) said an independent DSMB recommended continuation of the Phase III Oraxol 001 trial of Oraxol to treat metastatic breast cancer based on interim safety and overall response rate (ORR) data. The open-label, international...
21:23 , Oct 19, 2017 |  BC Week In Review  |  Clinical News

Theragnostics reports Phase I data for prostate cancer imaging agent

Theragnostics Ltd. (Bracknell, U.K.) said PET/CT imaging agent 68Ga-THP-PSMA did not lead to any adverse events in a Phase I trial in 14 patients with biopsy proven adenocarcinoma of the prostate. The trial compared the...